Xinyang Hu

机构：Implant Sciences (United States), Netherlands Heart Registration, Molecular Devices (United Kingdom), Communication University of Zhejiang, Second Affiliated Hospital of Zhejiang University, Zhejiang University, South China University of Technology · ORCID：0000-0002-6699-8470

发表论文 171 篇 · 总被引 6911 次 · h-index 43

代表论文

• Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial (2025 · The Lancet · 被引 38)
• FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1 (2025 · Circulation · 被引 25)
• Prognostic Value of Postpercutaneous Coronary Intervention Murray-Law-Based Quantitative Flow Ratio (2025 · JACC Asia · 被引 16)
• Deep learning prediction of ribosome profiling with Translatomer reveals translational regulation and interprets disease variants (2024 · Nature Machine Intelligence · 被引 12)
• Cholesterol sensing by the SCAP–FAM134B complex regulates ER-phagy and STING innate immunity (2025 · Nature Cell Biology · 被引 11)
• Engineered immunosuppressive dendritic cells protect against cardiac remodelling (2026 · Nature · 被引 10)